Alphatec
Alphatec's revenue rose 24.9% to $764 million in fiscal 2025. Its operating margin was −10.8%, up from −22.3% a year earlier. Free cash flow was $3 million. The diluted share count rose 5.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Alphatec does
Alphatec is a medical device company, based in Carlsbad, California, that makes products for spine surgery. It sells implants, surgical access systems, patient positioning tools, biologics (materials that help bone heal) and software, and it focuses on the spine only. Its customers are spine surgeons and the hospitals where they operate.
Alphatec sells in the United States through independent sales agents and its own sales representatives. It is only starting to sell implants abroad, in Australia, New Zealand and Japan. Revenue was $764.2 million in 2025. Alphatec says the number of surgeries using its products grew 22% in 2025.
It builds its products around complete surgical approaches, such as a method for operating from the side of the body with the patient lying face down. Its technology platform includes a full-body 3D imaging system from EOS Imaging, which it bought, software for surgical planning, a nerve-monitoring system called SafeOp and a navigation-enabled robot. It trains surgeons at its headquarters. In the filing it lists large, established medical device companies as its competitors.
Its biggest risks, as it describes them
- Competing against large, well-established medical device companies with more resources.
- Convincing spine surgeons to choose its products over rivals' products.
- Relying on independent sales agents and on a limited number of outside makers and suppliers.
- Hospitals and patients depending on insurance coverage and payments for its products.
- Failing to win regulatory clearances for new products, and a history of net losses.
Income statement
Alphatec lost money in fiscal 2025: a net loss of $143 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 187 | 85 | 221 | 139 | 161 |
| Debt incl. finance leases | 327 | 379 | 515 | 578 | 630 |
| Net debt (negative means net cash) | 140 | 295 | 294 | 439 | 470 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 4.1x | — | 6.6x | — | — |
| Interest coverage | −18.0x | −26.7x | −10.4x | −5.5x | −1.8x |
| Current ratio | 3.3x | 1.8x | 2.9x | 2.7x | 2.1x |
| Quick ratio | 2.4x | 1.1x | 2.0x | 1.6x | 1.3x |
Cash flow
Projections
Project Alphatec's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Alphatec reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | 4.5% | 5.9% | 25.3% |
| Altman Z'' | −3.47 | −4.35 | −4.63 |
| Accruals ratio | −16.3% | −14.9% | −24.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Alphatec side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alphatec | FY25 | 24.9% | −10.8% | 0.4% | −14.3% | — | 5 | |
| iRhythm | FY25 | 26.2% | −7.7% | 4.6% | −12.4% | — | 5 | Compare |
| Varex Imaging | FY25 | 4.1% | −3.3% | 2.2% | −2.9% | — | 6 | Compare |
| Novocure | FY25 | 8.3% | −23.5% | −11.6% | −33.0% | — | 4 | Compare |
| Inspire Medical Systems | FY25 | 13.6% | 5.6% | 8.6% | 14.2% | −4.8x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 120 | 102 | 92 | 113 | 145 | 243 | 351 | 482 | 612 | 764 |
| Revenue growth | −10.5% | −15.4% | −9.9% | 23.7% | 27.7% | 67.9% | 44.3% | 37.5% | 26.8% | 24.9% |
| Gross profit | 76 | 68 | 63 | 78 | 102 | 158 | 233 | 310 | 424 | 532 |
| Research and development | 9 | 5 | 10 | 14 | 19 | 32 | 44 | 70 | 81 | 76 |
| Operating income | −15 | −9 | −22 | −47 | −59 | −128 | −147 | −173 | −136 | −82 |
| Net income | −30 | −2 | −29 | −57 | −79 | −143 | −151 | −187 | −162 | −143 |
| Diluted EPS (US$) | −3.49 | −1.08 | −1.20 | −1.09 | −1.18 | −1.49 | −1.46 | −1.54 | −1.13 | −0.96 |
| Diluted shares (millions) | 9 | 13 | 35 | 52 | 67 | 96 | 103 | 121 | 143 | 150 |
| Cash flow | ||||||||||
| Cash from operations | −10 | −9 | −26 | −33 | −46 | −73 | −75 | −78 | −45 | 45 |
| Capital expenditure | 9 | 8 | 6 | 13 | 23 | 68 | 50 | 80 | 83 | 42 |
| Free cash flow | −19 | −16 | −32 | −46 | −70 | −142 | −125 | −159 | −128 | 3 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 15 | 0 | 0 | 62 | 0 | 55 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 5 | 11 | 18 | 36 | 41 | 81 | 73 | 74 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 22 | 29 | 47 | 108 | 187 | 85 | 221 | 139 | 161 |
| Debt incl. finance leases | 49 | 43 | 49 | 61 | 46 | 327 | 379 | 515 | 578 | 630 |
| Total assets | 94 | 85 | 130 | 170 | 261 | 572 | 521 | 805 | 776 | 791 |
| Total liabilities | 136 | 111 | 112 | 126 | 131 | 491 | 556 | 727 | 790 | 779 |
| Shareholders' equity | −42 | −27 | 18 | 44 | 130 | 81 | −35 | 78 | −14 | 12 |
| Margins and ratios | ||||||||||
| Gross margin | 63.3% | 67.1% | 69.0% | 68.4% | 70.8% | 64.9% | 66.4% | 64.3% | 69.4% | 69.6% |
| Operating margin | −12.8% | −8.8% | −24.5% | −41.7% | −40.6% | −52.6% | −41.9% | −36.0% | −22.3% | −10.8% |
| Net margin | −24.9% | −2.2% | −31.6% | −50.2% | −54.5% | −58.8% | −43.1% | −38.7% | −26.5% | −18.8% |
| Free cash flow margin | −15.7% | −16.1% | −35.0% | −40.7% | −48.0% | −58.3% | −35.5% | −33.0% | −20.9% | 0.4% |
| Rule of 40 (growth + FCF margin) | −26.2% | −31.4% | −44.9% | −17.0% | −20.3% | 9.6% | 8.8% | 4.5% | 5.9% | 25.3% |
| Return on capital | −97.4% | — | −112.3% | −78.2% | −73.7% | −70.0% | −48.3% | −43.4% | −27.0% | −14.3% |
| Return on equity | — | — | — | −186.3% | −91.0% | −135.9% | — | — | — | — |
| Return on assets | −24.9% | −2.6% | −27.1% | −38.1% | −36.6% | −34.3% | −27.7% | −28.1% | −20.5% | −18.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |